Brain+ A/S
CSE:BRAINP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beigene Ltd
SSE:688235
|
KY |
|
Multiplan Corp
NYSE:MPLN
|
US |
|
Haitong Securities Co Ltd
SSE:600837
|
CN |
Brain+ A/S
EPS (Diluted)
Brain+ A/S
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brain+ A/S
CSE:BRAINP
|
EPS (Diluted)
kr0
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
NNIT A/S
CSE:NNIT
|
EPS (Diluted)
kr0
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Monsenso A/S
CSE:MONSO
|
EPS (Diluted)
kr0
|
CAGR 3-Years
28%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Brain+ A/S
Glance View
Brain+ A/S is engaged in the developing of medical software to detect and treat the cognitive symptoms of dementia and the most common cause of dementia, namely Alzheimer's disease. The firm focuses on the development of digital treatment for dementia and Alzheimer’s disease by digital therapeutics. The Company’s main activities include the development of Cognitive Stimulation Therapy for the treatment of dementia, Computerized Cognitive Training for the treatment of earlier stages of Alzheimer’s and Starry Night memory test for early detection and monitoring of Alzheimer’s. The company offers a product called Digital CST assistant giving access to Cognitive Stimulation Therapy sessions, available in Danish.
See Also
What is Brain+ A/S's EPS (Diluted)?
EPS (Diluted)
-0
DKK
Based on the financial report for Dec 31, 2024, Brain+ A/S's EPS (Diluted) amounts to -0 DKK.
What is Brain+ A/S's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
41%
Over the last year, the EPS (Diluted) growth was 83%. The average annual EPS (Diluted) growth rates for Brain+ A/S have been 41% over the past three years .
